American Association of Health Plans

Over the next five years, list prices of protected prescription drugs are expected grow between 1% and 4% a year, while net prices are expected to decline by the same amount, IQVIA predicts.

PrEP could work for women too, but there's a gap in HIV rates among this demographic, especially Black women. Outside of PrEP's proven effectiveness, the below facts suggest the need for better promotion and more options.

In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.

Although chronic respiratory diseases remain the third leading cause of mortality, they have received less attention from the global community.

Research published in JAMA Health Forum shows that biosimilar savings have not trickled down to out-of-pocket savings for patients.